Mundipharma recruits dealmaker to develop EU business

Marco Cerato (pictured above) has left privately-held Swiss drugmaker Helsinn to join the Mundipharma network of independent associated companies.

Mr Cerato joins the European team as senior vice president, business development and strategic partnerships at UK-based Mundipharma, a group that focuses on developing partnerships to identify and accelerate meaningful technology across a diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars.

At Helsinn, Mr Cerato’s role was global head, business development and licensing. He has been involved with in-licensing and out-licensing deals along with alliance management and mergers and acquisitions.